scholarly journals Lymphoepithelioma-Like Carcinoma of the Breast: A Case Report Unveiling Several Clinical and Histopathological Challenges

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Tarek Aridi ◽  
Mohamad Fawwaz ◽  
Ahmad Kassab ◽  
Marwan Bahmad ◽  
Faisal Houcheimi ◽  
...  
Keyword(s):  
Case Reports ◽  
Progesterone Receptors ◽  
Radical Mastectomy ◽  
Residual Tumor ◽  
Excisional Biopsy ◽  
Axillary Lymph ◽  
Tumor Type ◽  
Estrogen And Progesterone Receptors ◽  
Type Iv ◽  
Criteria For Diagnosis

Lymphoepithelioma-like carcinoma (LELC) of the breast is an extremely rare tumor type. Histologically, it mimics undifferentiated nasopharyngeal carcinoma by demonstrating nests of neoplastic epithelial cells in a background of lymphoplasmacytic infiltrates. This paper reports a 62-year-old female patient with a 3 × 1.5 cm BI-RADS type IV breast mass diagnosed on excisional biopsy as LELC. The tumor is negative for estrogen and progesterone receptors and did not overexpress HER2/neu. Routine tests for clearance before surgery were performed, and patient was managed by a modified radical mastectomy with axillary lymph node dissection showing no residual tumor. Surgical CAse REports (SCARE) guidelines were followed for reporting our case. The rarity of LELC of the breast warrants the establishment and implementation of well-defined guidelines and criteria for diagnosis and management.

p29 Protein in Breast Cancer: Relation between Estrogen and Progesterone Receptors

1989 ◽  
Vol 75 (2) ◽  
pp. 113-116 ◽  
Author(s):  
Arturo Artero Morà ◽  
Ana Lluch Hernandez ◽  
Antonio Cano Sanchez ◽  
Francisco Javier Bueno Cañigral ◽  
Gregorio Martin Quetglas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptors ◽  
Premenopausal Women ◽  
Mean Value ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Immunoradiometric Assay ◽  
Estrogen And Progesterone Receptors ◽  
Primary Tumors ◽  
Er Status

An immunoradiometric assay was used to determine the presence of p29 protein in 68 breast cancer cytosols. The p29 values ranged from 0 to 1123 U/mg, with a mean value of 127+28.7 U/mg. Using a cutoff point of 20 U/mg the frequency of p29 positive tumors was about 55%. A quantitative and qualitative relation was found between p29 and estrogen receptor (ER), but not between p29 and progesterone receptor (PR). Discordance between p29 and ER status was found in 13 out of 68 tumors. Both the frequency of p29 positive tumors and the p29 values were significantly higher in postmenopausal than in premenopausal women, in a similar way to ER but different from PR. There was no difference in p29 content between primary tumor and metastasis. We did not find any relation among p29 primary tumors content and axillary lymph nodes involvement or tumor size.

scholarly journals Invasive papillary ductal carcinoma of the breast: A case report

2020 ◽  
Vol 10 (1) ◽  
pp. 17
Author(s):  
Amani S Hadi ◽  
Gamal Abdul Hamid ◽  
Refaat Al-Areqee ◽  
Wafa Abdullah
Keyword(s):  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Residual Tumor ◽  
Excisional Biopsy ◽  
Breast Mass ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
Invasive Papillary Carcinoma

The general rate of intrusive papillary carcinoma (IPC) is uncommon, representing for less than 1-2 % of invasive breast cancers. They are most generally observed in postmenposal females and uncommon in males. Invasive papillary carcinomas are low grade tumors originating from large or dilated ducts. They are make out of all around outlined solid nodules of monotones neoplastic cell separated by network of fibrovascular cores, IPC is a remarkable sort of breast cancer and regarded of whether it is in-situ or invasive, it has brilliant prognosis. We presenting two cases of invasive papillary carcinoma in male and female; A case of 55years postmenoposal female who presented with history of left breast mass, which this mass notice after trauma same site for 1 year ago the mass gradually increase in size no tenderness, no signs of inflammation. Excisional biopsy was performed and specimen was histopathology diagnosed as invasive papillary carcinoma, left MRM was performed and histopathology diagnosis confirmed and without residual tumor seen in submitted slides and all submitted lymph nodes were free of tumor infiltration (0/14). IHC show ER and PR negative with HER-2 positive. The second case 70 years male presented with right breast mass and history of post-trauma since one year back with gradual increase in size, right radical mastectomy done and histopathology diagnosed as invasive papillary carcinoma, IHC was done ER and PR positive with HER2- negative.

Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer

2008 ◽  
Vol 94 (6) ◽  
pp. 838-844 ◽  
Author(s):  
Bozica Matkovic ◽  
Antonio Juretic ◽  
Viktor Separovic ◽  
Irena Novosel ◽  
Robert Separovic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Axillary Dissection ◽  
Radical Mastectomy ◽  
Antigen Expression ◽  
Clinicopathological Parameters ◽  
Published Data ◽  
Axillary Lymph ◽  
Tumor Type ◽  
Axillary Lymph Node Metastases ◽  
Her 2

Aims and Background Recent publications of breast cancer classification based on gene expression profile analyses indicate that medullary breast carcinomas (MBC) may be considered part of the basal-like carcinoma spectrum made up of ER-negative, PR-negative and HER-2-negative cells (“triple-negative phenotype”). On the other hand, there are also data showing that a proportion of MBC and atypical MBC (AMBC) is ER, PR and/or HER-2 positive. Therefore, we have decided to immunohistochemically analyze ER, PR, HER-2 and basal/myoepithelial markers CK5/6, p63 and EGFR expression in our archival paraffin-embedded MBC and AMBC samples from 48 patients. Methods Immunohistochemical evaluation of samples which were derived from patients operated on at our two hospitals between 1999 and 2005. Results Typical MBC was found in 39 patients and AMBC in 9 patients. The patients ranged in age from 32 to 84 years (median 55). Modified radical mastectomy with axillary dissection was performed in 30/48 patients (63%) while breast segmentectomy with axillary dissection was performed in 18/48 patients (37%). Metastases in axillary lymph nodes were observed in 15/48 patients (31%). ER positivity was present in 3/48 patients (6%), PR positivity in 8/48 (17%), and a positive HER-2 reaction was present in 14/48 patients (29%). CK 5/6 was positive in 20/48, p63 in 24/48 and EGFR in 8/48 patients. Adjuvant therapy was applied in all but 2 patients. Alive were 45/48 (94%) of patients. With the exception of PR expression, 39 patients with typical MBC and 9 patients with AMBC were comparable in the analyzed parameters. Positive HER-2 antigen expression in the analyzed sample was not found to be associated to a statistically significant degree with the MBC or AMBC histological tumor type, tumor size, axillary lymph node metastases, ER and PR status nor with patient survival. Conclusions The data from our study seem to be generally comparable with the relatively scarce published data on clinicopathological parameters of MBC and AMBC.

scholarly journals NI-19 Use of 11C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide

2020 ◽  
Vol 2 (Supplement_3) ◽  
pp. ii14-ii14
Author(s):  
Takaaki Beppu ◽  
Yuichi Sato ◽  
Toshiaki Sasaki ◽  
Kazunori Terasaki ◽  
Kuniaki Ogasawara
Keyword(s):  
Adjuvant Chemotherapy ◽  
Small Sample Size ◽  
Standardized Uptake Value ◽  
Progression Free Survival ◽  
Residual Tumor ◽  
Small Sample ◽  
Tumor Type ◽  
Diffuse Astrocytoma ◽  
Significant Difference ◽  
Met Pet

Abstract Background: The aim was to clarify whether positron emission tomography with 11C-methyl-L-methionine (met-PET) is useful to decide on discontinuation of TMZ-adjuvant therapy in patients with residual diffuse astrocytic tumor. Methods: Subjects were 44 patients with residual tumor comprising 17 with IDH1-mutant diffuse astrocytoma (DA), 13 with IDH1-mutant anaplastic astrocytoma (AA), and 14 with IDH1-wild glioblastoma (GB). All patients received TMZ-adjuvant chemotherapy (median, 12 courses), and whether to discontinue or continue TMZ-adjuvant chemotherapy was decided on the basis of the tumor-to-normal ratio in standardized uptake value from met-PET (T/N); patients with T/N < 1.6 immediately discontinued TMZ, and patients with T/N > 1.6 were either to continued or discontinued TMZ. Progression-free survival (PFS) was compared between patients with T/N > 1.6 and T/N < 1.6 in each tumor type. Median observation period was 434 days after met-PET scanning. Results: The number of patient who underwent recurrence was 10 in DA, 7 in AA, and 11 in GB. All patients showing T/N > 1.6 underwent tumor recurrence. PFS was significantly longer in patients with T/N < 1.6 than T/N > 1.6 in DA and AA (p < 0.01 in both types), but was no significant difference between 2 groups in GB (p = 0.06). Sixteen of 17 patients (94%) in DA and AA showed recurrence from residual tumor, whereas 4 of 11 patients (36%) in GB showed recurrent tumor at remote regions which were different from residual tumor. Conclusions: The present study suggested that met-PET is beneficial to decide to discontinue adjuvant chemotherapy with TMZ in patients with residual tumors of DA and AA, but not useful for patients with GB. Reasons for unsuccessful results in GB might have been small sample size, failure of establishing the cut off value in T/N, recurrences at remote regions where not be assessed by met-PET.

scholarly journals Small Cell Carcinoma of the Uterine Cervix in a Pregnant Patient Diagnosed with Liquid Based Cytology and Cell Block Immunocytochemistry

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Mawuli F. Attipoe ◽  
Charles D. Sturgis
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Uterine Cervix ◽  
Case Reports ◽  
Pregnant Patient ◽  
Small Cell ◽  
Tumor Type ◽  
Cell Block ◽  
Current Case ◽  
Small Series

Definitive cytomorphologic diagnosis of small cell carcinoma of the uterine cervix is possible but can be challenging in routine cervicovaginal cancer screening specimens. Several small series of reported cases of cervical small cell carcinoma have shown this uncommon malignancy to represent fewer than 2% of all invasive cervical cancers. This tumor type is associated with poor prognosis and rapid disease progression and can develop to an advanced stage in the interval between screening visits. Only rare case reports of small cell carcinoma arising in gravid cervices are known. In the current case a 29-year-old, gravida 6, para 2, pregnant (10-week gestation) female presented with postcoital bleeding. A definitive diagnosis of small cell carcinoma of the cervix was made possible by liquid based Pap testing with ancillary cell block preparation allowing for immunocytochemical characterization of the lesional cell population.

Local Recurrence of Breast Cancer after MammoSite® Brachytherapy

2006 ◽  
Vol 72 (9) ◽  
pp. 798-801
Author(s):  
Matthew Voth ◽  
Raye Budway ◽  
Angela Keleher ◽  
Philip F. Caushaj
Keyword(s):  
Breast Cancer ◽  
Treatment Plan ◽  
Breast Conservation ◽  
Radical Mastectomy ◽  
Axillary Lymph ◽  
Ultrasound Guided ◽  
Breast Pathology ◽  
Poorly Differentiated ◽  
Her 2 ◽  
Negative Tumor

Women undergoing breast conservation therapy (BCT) for stage 1 breast cancer have adjuvant external beam radiotherapy (EBR). In addition, the use of brachytherapy radiation is being used. We present two local tumor recurrences for review. Our first patient underwent BCT, sentinel lymph node biopsy (SLNBx) and MammoSite® brachytherapy for a T1N0M0 infiltrating ductal carcinoma (IDC) of the right breast. Pathology: 0.6 cm poorly differentiated ER, PR, and Her-2/ Neu negative IDC. At 18 months, she had palpable axillary lymph nodes. Fine needle aspiration and ultrasound-guided core biopsy of a nodule showed IDC. She underwent modified radical mastectomy (MRM) and EBR. Our second patient underwent BCT, SLNBx, and MammoSite® brachytherapy for a T1N0M0 IDC of the left breast. Pathology: 0.8 cm poorly differentiated, ER+, PR-, and Her-2/Neu negative tumor. At 18 months, a retroareolar mass was detected. Ultrasound guided core needle biopsy showed recurrent IDC. She chose a re-excision and EBR and not MRM. Pathology: 1.3 cm poorly differentiated, ER+, PR-, and Her-2/Neu negative tumor. Our 2 recurrences were >2 cm away from the lumpectomy site and therefor outside the 1 cm treatment plan of the MammoSite® catheter. Both recurrences were biologically identical to the initial tumors and are felt to be local failures rather than new primaries.

Sign in / Sign up

Export Citation Format

Share Document